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Exposure Assessment Approaches for
Engineered Nanomaterials
Linda C. Abbott1,∗ and Andrew D. Maynard2
Products based on nanotechnology are rapidly emerging in the marketplace, sometimes
with little notice to consumers of their nanotechnology pedigree. This wide variety of nan-
otechnology products will result (in some cases) in unintentional human exposure to pur-
posely engineered nanoscale materials via the dermal, inhalation, ingestion, and ocular path-
ways. Occupational, consumer, and environmental exposure to the nanomaterials should
be characterized during the entire product lifecycle—manufacture, use, and disposal. Mon-
itoring the fate and transport of engineered nanomaterials is complicated by the lack of
detection techniques and the lack of a defined set of standardized metrics to be consis-
tently measured. New exposure metrics may be required for engineered nanomaterials,
but progress is possible by building on existing tools. An exposure metric matrix could or-
ganize existing data by relating likely exposure pathways (dermal, inhalation, ocular, in-
gestion) with existing measurements of important characteristics of nanoscale materials
(particle number, mass, size distribution, charge). Nanomaterial characteristics not com-
monly measured, but shown to initiate a biological response during toxicity testing, sig-
nal a need for further research, such as the pressing need to develop monitoring devices
capable of measuring those aspects of engineered nanomaterials that result in biological
responses in humans. Modeling the behavior of nanoparticles may require new types of ex-
posure models that individually track particles through the environment while keeping track
of the particle shape, surface area, and other surface characteristics as the nanoparticles are
transformed or become reactive. Lifecycle analysis could also be used to develop conceptual
models of exposure from engineered nanomaterials.
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1. OVERVIEW
Products based on nanotechnology are rapidly
emerging in the marketplace, sometimes with little
notice to consumers of their nanotechnology pedi-
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gree. Uses of this emerging technology range from
the mundane to those of great importance to soci-
ety.(1−3) The wide variety of nanotechnology prod-
ucts in use and under development could result (in
some cases) in unintentional human exposure to pur-
posely engineered nanoscale materials via the der-
mal, inhalation, ingestion, and ocular pathway.(4,5)
Intentional exposure to nanomaterials—such as tar-
geted drugs—may result in nanomaterial transport
to organs and tissues usually protected from the ma-
terial in bulk form. Engineered nanomaterials may
also be transported into the environment where ad-
ditional exposure may occur.
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The emergence of nanotechnology-based con-
sumer products signals an urgent need to examine
pathways of exposure to products of nanotechnol-
ogy and quantify these exposures with toxicologically
relevant metrics. Conventional exposure monitoring
techniques may not adequately characterize nano-
materials. Analysis of traditional exposure pathways
may not provide adequate data for risk characteriza-
tion and, ultimately, risk management.
Not all nanotechnology-enabled products will
lead to exposure, and not all exposures will lead to
new risks. For instance, modern semiconductors that
are fabricated at the nanoscale are a clear product of
nanotechnology, but their use is unlikely to lead di-
rectly to nanomaterial exposure. Materials and prod-
ucts of most concern are those with the potential
to release nanoscale materials into the environment
that may lead to biologically relevant exposure.(6)
These include aerosols, powders, and suspensions of
engineered nanometer-diameter particles (nanopar-
ticles) and micrometer-scale agglomerates or ag-
gregates of these particles. Products that may re-
lease nanostructured materials into the environment
during manufacture, use, and disposal are also
potentially of concern, if the released material has a
biologically active nanostructure.(6)
Exposure assessment plays a critical role in a
risk assessment by providing an estimate of the con-
tact with a chemical, physical, or biological hazard
by a receptor. The mere presence of a hazard is
not enough to support a finding of risk—without ex-
posure to the hazard, the human or environmental
receptor is not directly at risk. Estimation of expo-
sure requires that the unit of measurement match
the toxicologically relevant aspects of the contact be-
tween the hazard and the receptor. Toxicologically
relevant aspects of contact with a nanoparticle may
include particle size, particle number, surface area,
surface chemistry, charge state, degree of agglomer-
ation, and shape.(7,8) Unique characteristics of nano-
materials that may become toxicologically relevant
include the surface to mass ratio, strength, durabil-
ity, conductivity, reactivity, solubility, and the ability
to adsorb and carry other chemicals.(7)
Exposure should be measured in a manner con-
sistent with the metric used to characterize the haz-
ard of the nanomaterial. Multiple exposure events, as
well as multiple exposure pathways, may need to be
considered. Exposure measurements should be col-
lected at the spatial and temporal scale relevant to
the effect on the receptor. Exposure durations could
range from short-term exposures measured in sec-
onds or minutes to lifetime exposures measured in
years and may include acute, subchronic, chronic,
and lifetime exposures. A time-weighted average
over the relevant duration may be more meaningful
than the cumulative concentration for some classes
of nanomaterials. Exposure of nonhuman organisms
will vary based on habitat. Transfer of nanomate-
rials between trophic levels in the food chain must
be considered when developing ecological exposure
metrics.
A part of exposure assessment is describing the
fate and transport of the hazardous material or agent
through the environment. Transformations of the
material into other chemical or physical forms may
affect the distribution or toxicity of the material. Ag-
glomeration of nanoparticles into larger structures is
one example of a physical transformation that may
affect transport, fate, and hazard.(6) The environmen-
tal persistence or durability of a chemical or physical
form of the material should also be considered.
2. SPECIAL IMPLICATIONS OF
NANOTECHNOLOGY FOR
EXPOSURE ASSESSMENT
The characteristics of nanotechnology that make
it such a powerful new tool also lead to novel mecha-
nisms by which humans and ecological receptors may
become exposed to some engineered nanomaterials.
Not only does the size of engineered nanoparticles
(for example) influence the distribution of these ma-
terials in the environment, but the shape, the coating,
and other surface characteristics also control the fate
and environmental transport of these materials.(9)
Some nanomaterials exhibit quantum effects, the dis-
continuous behavior due to quantum confinement ef-
fects in materials with delocalized electrons,(10) which
can lead to abrupt size-related changes in physical,
chemical, and biological behavior at the nanoscale.
Transport and fate in the environment could poten-
tially be affected by quantum effects. Heterogeneous
nanomaterials contain an internal material that dif-
fers from the external core shell,(8) potentially allow-
ing the internal material to be transported through
the environment more like the material in the outer
shell.
While nanomaterials exhibit unique properties
that may increase their hazard potential, the de-
sign of the engineered materials and their use in
products may reduce the likelihood of exposure in
some instances. Nanoparticles fixed within a medium
will not move through the environment and will not
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result in human or environmental exposure while
they remain fixed in place.(10) It should be noted,
however, that these particles may be freed from the
medium in which they are embedded if the medium
is physically or chemically altered, in which case ex-
posure to the nanoparticles is possible.
Manufactured nanoparticles can be homoge-
neous in shape and size, unlike nanoparticles inciden-
tally produced in the environment.(7) Thus, exposure
to manufactured nanomaterials may result in high
doses of materials with biologically relevant char-
acteristics (e.g., high surface area, reactivity), even
when the dose in terms of material mass is relatively
low. While this disconnection between the biolog-
ically relevant dose and mass of material also ap-
plies to naturally occurring nanoparticles, engineered
nanoparticles may exhibit this characteristic more
strongly because their size and shape are the result
of a controlled manufacturing process.
The unconventional behavior of nanomaterials
makes it difficult to predict in many cases the dis-
tribution and effect of these materials in the human
body or the environment. Manufactured nanoma-
terials may be transported along traditional expo-
sure pathways (ingestion, dermal, inhalation) but in a
manner unlike conventional materials.(7,9) Nanopar-
ticles can be engineered to overcome the blood-
brain barrier that conventional materials do not
cross.(11,12) Some nanoparticles may possibly pene-
trate skin to greater degree than conventional ma-
terials and translocate within the body, although
further research is needed to establish when and how
this might happen.(13−15) Further studies have shown
the potential of nanoparticles once in the dermis to
localize to regional lymph nodes.(16) However, sev-
eral studies have shown no evidence of nanopar-
ticle penetration through healthy skin.(17−19) Some
nanoparticles may cross from the lungs to the blood-
stream following inhalation,(20) and can be trans-
ported along nerve cells, such as those connecting
receptors in the nose to the brain.(21) Nanoparticles
can efficiently be translocated through the epithe-
lial cells and mucosal lining of the gastrointestinal
tract.(22) They can also be translocated through other
mucosa, such as the nasal lining, the vagina, the lungs,
and the oral cavity.(7)
Nanoparticles may form aggregates or agglom-
erates that influence their transport in the envi-
ronment and human body. Nanoparticles that form
agglomerates may simultaneously act at the nano-
and microscale as do some nanopowders.(23,24) Ag-
glomeration may influence whether and to what
extent organisms in the environment are exposed to
the nanomaterial.




3.1. Developing Better Conceptual
Models of Exposure
Life-cycle analysis could be used to develop con-
ceptual models of nanomaterial exposure. Taking
a life-cycle approach to problem formulation could
guide development of likely exposure scenarios and
identify potential receptors.(25) Monitoring data and
model simulations could be used to refine and val-
idate these conceptual models. Several frameworks
incorporate a life-cycle approach into risk assess-
ment.(26−28)
Case studies of existing nanomaterials, such as
the Organization for Economic Cooperation and De-
velopment’s (OECD) Working Party on Manufac-
tured Nanomaterials or Environmental Protection
Agency (EPA) case studies,(29,30) will also provide
exposure data to develop conceptual models of ex-
posure for new nanomaterials. These detailed case
studies examining the fate and transport of nano-
materials in the environment, including exposure to
humans through occupational and nonoccupational
settings, will increase our understanding and aid in
development of conceptual models of exposure. Be-
cause the EPA case studies use the comprehensive
environmental assessment framework, they will in-
form conceptual models incorporating a life-cycle ap-
proach to risk analysis.(26)
3.2. Developing New Exposure Scenarios
New human and environmental exposure scenar-
ios over the product lifecycle are necessary to con-
sider changes in exposure during manufacture, use,
misuse, and disposal. Exposure is often application-
specific. Better understanding of the lifecycle of
these new products will result in a more compre-
hensive analysis of human and environmental expo-
sure.(3)
The exposed population will change over the
product lifecycle. Workers are perhaps at the great-
est risk of exposure to nanomaterials currently as
new products are undergoing research and test-
ing; eventually workers will also be exposed during
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commercial manufacturing(6,31) and recycling. Occu-
pational studies have focused on inhalation exposure,
but there is a need for examining exposure through
contact with skin (dermal sensitization) and ocular
exposure as well as evaluating incidental ingestion of
the nanomaterial during manufacture.
Consumer exposure scenarios must address ex-
posure pathways associated with the intended use of
the product as well as misuse or use at higher ap-
plication rates than anticipated.(3) Transformation of
the nanomaterial and its persistence in the environ-
ment will be important consideration for consumer
exposure. The type of exposure to the nanomate-
rial may change during its use. A nanomaterial in-
corporated in a textile product may result in dermal
exposure, but may also include oral exposure to a
child mouthing the cloth.(3) Washing, drying, and
ironing textiles may alter the exposure to nanomate-
rials.(32) Exposure to light or abrasion may also af-
fect the movement of the nanomaterials from the
textile into other environmental media. Nanomate-
rials freed from the textile matrix may accumulate in
dust.(33)
Nanomaterials in consumer products may be-
come dislodged or freed from the product matrix
during use or disposal.(3,32) Nanomaterials that are
no longer contained in the product matrix may be
transported throughout the environment or human
body differently than the nanomaterials within the
product, creating novel exposure scenarios. For ex-
ample, nanomaterials originally in a textile matrix
may be released into washwater during laundering(32)
or nanomaterials used in packaging may present in-
halation exposure if the nanomaterial is freed from
the product matrix while the packaging is heated or
torn off.(34)
Disposal of products containing nanomaterials
creates the possibility of transport through the envi-
ronment and possibly secondary exposure through
contact with a waste stream. For example, nanosilver
particles accumulated in biosolids at a waste water
treatment facility, due to the laundering of
textiles containing nanosilver, could be transported
to aquatic environments or possibly to terrestrial
systems if the biosolids are used as fertilizer.(32) The
nanosilver particles from the textile could potentially
be applied to a food crop if biosolids are approved
for that use.
Exposure scenarios for nonhuman species must
address nanomaterial transport through the environ-
ment following accidental release or disposal in a
waste stream. The movement of nanomaterials in the
food chain and potential bioaccumulation in some
species will need to be examined through monitor-
ing studies. At least one laboratory study demon-
strated that quantum dots may be transferred to
higher trophic levels in a simple aquatic invertebrate
food chain.(35)
3.3. Collecting New Measurements of Exposure
Shape, surface area, surface chemistry, surface
charge, size, chemical composition, crystal struc-
ture, porosity, and agglomeration state have all been
suggested as characteristics to measure in nanomate-
rials.(7) In many cases, unconventional or new expo-
sure metrics will be needed to characterize nanoma-
terials.(8) Exposure assessments based solely on the
concentration or mass of a material in a particular
environmental medium (food, water, air, soil, etc.)
will not adequately measure exposure to functional
or structural properties of the nanomaterial, in many
cases. A standard set of potentially relevant mea-
surements collected routinely during exposure stud-
ies is critical to understanding how nanomaterials are
transported through the environment and to facili-
tate the development of mechanistically based expo-
sure models.
The lack of clarity as to which characteristics
are associated with the hazard potential of various
nanomaterials creates uncertainty as to what mon-
itoring measurements should be made. Monitoring
studies are crucial to developing adequate exposure
estimates, yet the tools to detect the products of
nanotechnology are not well developed. In addition,
without standard approaches to characterizing nano-
materials, it is difficult to compare studies and de-
termine what attribute is associated with an adverse
effect. Comparisons between studies using a standard
set of measurements for 14 nanomaterials may soon
be possible as results from the OECD nanomaterial
testing program become available.(29)
The toxic effects of many chemical hazards can
be related to the chemical concentration available
in air, water, soil, food, a product, or a carrier or
transport medium.(36) It is unlikely that a single mea-
surement, such as concentration in an environmen-
tal medium, will adequately characterize the relevant
attributes of many nanomaterials. The mass-based
exposure assessment metrics traditionally used to
evaluate exposure to chemical hazards (e.g., mg
chemical/kg organism from in vivo toxicity studies)
may miss the toxicologically relevant aspects of ex-
posure to nanotechnology products.(23)
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Since the mid 1900s, health-related measure-
ments of airborne particles have been characterized
in terms of the mass of material per unit volume of
air. Yet as has been discussed, a number of studies
have indicated that, on a mass for mass basis, certain
nanometer-scale insoluble particles small enough to
deposit in the alveolar region of the lungs may be
more toxic than larger particles with a similar com-
position.(9,37−45) In addition, epidemiology studies re-
lating ambient aerosol exposure to health conducted
since the early 1990s have demonstrated an increase
in health impact from particles smaller than 2.5 μm
compared to those smaller than 10 μm on a mass
for mass basis.(46−56) And while only limited data
on the health impacts of occupational nanoparticles
exist, there is some evidence to suggest that health
effects associated with inhaling nanometer-scale
particles generated in hot processes such as metal
processing and welding are greater than mass-based
exposures would indicate.(57,58)
Overall, it is clear that mass concentration
will not always be a relevant exposure metric for
engineered nanomaterials on its own. There is
toxicology-based evidence that aerosol surface-area
is an appropriate exposure metric for some low solu-
bility particles.(40−42,59) However, it is clear that fac-
tors in addition to surface area also play a role,
including surface chemistry.(41,60,61) There are also
indications that in some instances particle number
within specific particle size ranges may be impor-
tant.(57) And recent studies on particle translo-
cation within the body have further indicated a
size-dependency on the likelihood of deposited parti-
cles moving from the respiratory system to other or-
gans.(21,22,62)
This uncertainty makes it difficult to evaluate ex-
posure to airborne nanostructured materials appro-
priately, whether in toxicity studies or whether while
monitoring human exposure. Relying on mass con-
centration will clearly not be appropriate in all sit-
uations, and alternative measurement methods and
approaches will need to be used. Selecting the right
approach for a given situation is not trivial though,
and is compounded by a general lack of suitable
equipment for making such measurements.
Measurement methods are currently available
that allow nanoparticle characteristics to be evalu-
ated. These include techniques such as electron mi-
croscopy, particle mobility analysis, dynamic light
scattering, and field flow fractionation.(8,63,64) Yet
many of these techniques are associated with special-
ized research tools, and are not well suited for rou-
tine exposure monitoring. In the long run, practical
exposure monitoring instruments will be needed that
provide relevant information on airborne and water-
borne nanoparticles and nanostructured particles, in
an efficient and cost-effective way.(65) In the near-
term, a universal aerosol monitor has been proposed
for monitoring airborne exposures, which is capable
of providing personal exposure measurements to all
three metrics—number of particles in air, mass, and
surface area—simultaneously, and is sufficiently in-
expensive to encourage widespread use.(8,65) While
not covering all relevant metrics, such an instrument
would enable many potentially relevant metrics of
exposure to be tracked.(8)
The identification of biomarkers associated with
exposure to various types of nanomaterials will allow
monitoring of exposure of internal dose. If biomark-
ers are developed, screening for past exposure in the
population could occur. Reconstruction of past ex-
posure events may be possible following detection of
biomarkers in an individual. Guidelines for the inter-
pretation of the biomarkers will also need to be de-
veloped although the basic requirements of stability
and specificity apply here as they do in conventional
biomarkers. The development of such biomarkers for
engineered nanomaterials could be informed by the
radiological exposure research and the identification
of stable intrachromosomal biomarkers of past ex-
posure to ionizing radiation using multiband fluores-
cence in situ hybridization techniques.(66)
3.4. New Fate and Transport Models
Models that only account for chemical concen-
tration in the environment will be inadequate for
nanomaterials if the environmental behavior or the
relevant toxicological attribute of the nanomaterial
is related to particle size, surface area, particle shape,
porosity, or surface chemistry. Before much progress
can be made refining existing fate and transport mod-
els or developing new ones, the processes that in-
fluence the fate and transport of nanomaterials will
need to be elucidated.
Modeling the behavior of nanoparticles may re-
quire new types of exposure models that individu-
ally track particles through the environment while
keeping track of the particle shape, surface area
and other surface characteristics as the nanoparti-
cles are transformed or become reactive. Some exist-
ing particle-based models may provide an approach
that could be modified to address the movement of
engineered nanomaterials through different types of
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environmental media. These models include those
that estimate the transport and deposition of air pol-
lutants(67−69) and other nonintentionally produced
nanoparticles, such as those generated by forest
fires,(70−73) volcanoes, dust storms, diesel exhaust,(74)
and other traffic pollutants.(75)
Some fate studies suggest that nanoparticles do
not follow traditional particle dynamics established
for larger particles.(76,77) The fate and transport of
nanoparticles in natural environments may be in-
fluenced by the presence of natural organic matter
that allows nanoparticles to deaggregate in model
aquatic ecosystems.(78,79) Models to estimate the
movement of particles that have formed agglomer-
ates are under development.(80) Particle-based mod-
els for biofilm development may also be useful in
modeling nanoparticles in the environment.(81)
3.5. Developing an Exposure Metric-Matrix to
Organize Existing Information on Exposure
Identifying the most relevant exposure metrics
for nanomaterials will be driven by the results of
toxicological studies that determine the toxic mode
of action of the engineered nanomaterials and by
epidemiological studies that link adverse health out-
comes with exposure to engineered nanomaterials.
Until these studies have been conducted, especially
the toxicological experimentation, there will be un-
certainty over which exposure metrics are most ap-
propriate. Organizing the existing studies into an
exposure metric matrix that relates likely exposure
pathways (e.g., dermal, inhalation, ocular, ingestion),
measurements of physical and chemical character-
istics (e.g., number of particles, mass, size distribu-
tion, charge, etc.), and biological responses in the
study organism would highlight data gaps. Synthesiz-
ing information across categories of nanomaterials—
single-walled carbon nanotubes, multiwalled carbon
nanotubes, metals, and oxides, for instance—could
lead to identification of patterns of biological re-
sponse associated with levels of one or more of the
exposure metrics and the possibility of extrapolat-
ing to other nanomaterials sharing similar physical or
chemical attributes. The matrix could be expanded
to include different life stages of humans or other
organisms. Nanomaterial characteristics that are not
easily measured outside the laboratory, but shown to
initiate a biological response during toxicity testing,
indicate the need for new exposure monitoring tech-
niques.
4. MODIFICATIONS TO RISK MANAGEMENT




Risk management and risk communication will
require a clearer understanding of the mechanisms
through which humans and environmental recep-
tors could be exposed to engineered nanomaterials.
Stakeholders will require explanations of the new
exposure metrics used. Interpreting the meaning of
new exposure metrics will present a challenge for
risk communicators. It is likely that no single met-
ric will completely characterize exposure. Risk man-
agers and communicators will need to explain why
there are not uniform metrics for all types of nano-
materials. Risk managers should understand the clas-
sifications and categories of nanomaterials and how
they relate to likely exposure by humans or in the
environment.
Risk managers will no longer be able to rely only
on estimates of the mass concentration of a material
in the environment but will need to consider other
metrics depending upon the type of nanomaterial at
issue. Familiar exposure estimates that risk managers
currently rely upon to regulate chemical hazards—
daily dietary intake and permissible exposure con-
centrations(31)—will need to be augmented with new
exposure estimates.
As more diverse nanotechnology-based products
appear in the marketplace, there is an increased like-
lihood that humans will be exposed to multiple types
of engineered nanomaterials. The different types of
nanoparticles may be transported along the same en-
vironmental pathways and use the same routes of
entry into the human body. Or it may transpire
that engineered nanoparticles with different physic-
ochemical characteristics may follow completely dif-
ferent exposure pathways. Risk managers will need
to examine exposure to multiple types of nanoparti-
cles. An appropriate regulatory metric will be needed
synthesizing the cumulative and aggregate exposure
to multiple nanomaterials. Evaluating a series of al-
ternatives to reduce exposure to multiple nanomate-
rials and environmental media may require the de-
velopment of more complex decision analysis tools
for the risk manager.(82,83)
Coordination between the federal agencies will
become increasingly important to federal risk man-
agers. The lifecycle of nanomaterial products will
cause these products to fall within the purview of
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many different agencies as the products are manu-
factured, packaged, distributed, purchased by con-
sumers, and eventually disposed of or recycled. Risk
mitigation will require coordination between agen-
cies that may otherwise not have interactions with
one another.
5. PRIORITIES FOR FUTURE RESEARCH
Monitoring of nanomaterials in the body and
environment is critical. Before more refined expo-
sure models can be constructed to estimate fate
and transport, basic research is needed to increase
our understanding of the processes controlling the
distribution of these materials in the environment. A
recent pilot study suggesting that some carbon nan-
otubes can induce precancerous growths similar to
those preceding mesothelioma following asbestos ex-
posure highlights the urgent need to collect more
data on real-world exposures to nanomaterials.(84)
An exposure baseline for nanomaterials will be use-
ful in assessing cumulative exposure from existing
materials.
Developing monitoring tools to measure nano-
materials in the environment across the spatial
and temporal scales relevant to risk assessors is a
top priority.(65) Uncertainty over what to measure
may have resulted in few monitoring and expo-
sure measurements—this trend will have to be re-
versed.(85) Standardizing the measurements collected
during monitoring will advance our understanding
of exposure.(86) An uncoordinated set of monitoring
measurements does not facilitate comparisons be-
tween studies, exposure pathways, or nanomaterials.
More complex monitoring devices will be needed in
the future. In the short term, there is a need to de-
velop indirect measurements of the appropriate ex-
posure metrics when these metrics are not directly
measurable with today’s monitoring equipment.
Some pathways of exposure to engineered nano-
materials are poorly studied. Exposure through in-
gestion will be the most common pathway for expo-
sure to nanomaterials in water, food, food additives,
dietary supplements, and some drugs, yet there are
few studies addressing this pathway.(87) Foods and
dietary supplements containing engineered nano-
materials are not common.(88) The migration of
engineered nanomaterials from packaging or food
contact materials to food is another potential con-
tributor to the ingestion exposure pathway. Charac-
terizing nanomaterials in biological matrices, such as
foods before and during digestion, may require new
detection and quantification methods.
Incidental ingestion of nanomaterials from the
skin via hand-to-mouth activity and from swallowing
nanomaterials that have been cleared from the res-
piratory tract via mucociliary escalator is also poorly
studied.(89) Hand-to-mouth ingestion exposure is just
beginning to be addressed, as shown in the recent
EPA case study on nanoscale titanium dioxide in wa-
ter treatment and sunscreen.(30) Federal agencies are
not devoting many resources to this important ex-
posure pathway.(85,90−92) Exposure to nanomaterials
via the inhalation pathway has been more thoroughly
studied than exposure via other pathways,(80,93) but
even with this pathway there is a need for more real-
time monitoring studies.
Many exposure scenarios involving consumer
products lack monitoring data. An important data
gap is monitoring chronic exposure to nanomaterials
through contact with consumer products that have a
long expected use period, such as textiles.(3,91)
Implementing life-cycle approaches will require
research on exposure to nanomaterials during recy-
cling and disposal. Recycling of nanomaterials may
result in new occupational exposures as materials are
reformulated or recovered from the product matrix.
Disposal of nanomaterials may result in environmen-
tal exposure if the nanomaterials are released from
the disposal site.
By the U.S. government’s estimate, only 2% of
annual federal research and development projects
addressing nanotechnology environment, health, and
safety impacts are directed toward exposure assess-
ment.(91) This has been criticized as being an over-
estimate of the true funding levels by some.(94) The
paucity of exposure assessment studies currently be-
ing funded and the lack of standardization in moni-
toring are preventing risk assessors from conducting
comprehensive and timely assessments of nanomate-
rials.
6. CONCLUDING REMARKS
Exposure assessment of nanomaterials will con-
tinue to be an exciting area of development within
risk assessment. Although the unique characteristics
of nanomaterials will continue to provide measure-
ment and modeling challenges, the exposure asses-
sor’s toolbox is not empty. Much progress can be
made by building on existing tools rather than de-
signing an exposure assessment protocol de novo.
Mass concentration is not likely to be the most
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important metric for assessing exposure in many
cases, but it can be used as a starting point to be used
with other metrics as they are developed. Mass con-
centration, in combination with other information,
may be used to estimate some of the other more bio-
logically relevant attributes of the nanomaterial, such
as surface area. Organizing the exposure measure-
ments from existing studies by nanomaterial, mea-
surement type, pathway, and effect on the organism
will highlight data gaps and may identify possibilities
for extrapolation from one class of material to an-
other.
There is a pressing need to develop monitoring
devices capable of measuring those aspects of en-
gineered nanomaterials that result in biological re-
sponses in humans. It is important to collect the mea-
surements that can be made with today’s generation
of monitoring devices even if the exposure metric of
interest can only be indirectly measured. Develop-
ment of better monitoring techniques and exposure
assessment methods for nanomaterials will advance
the risk management of these materials.
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